Publications by authors named "Andi Leubitz"

Claim this Profile
A
A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Escalation Study to Evaluate the Safety and Pharmacokinetics of ELX-02 in Healthy Subjects.
Andi Leubitz, Frederic Vanhoutte, Ming-Yi Hu, Kaela Porter, Efrat Gordon

Clin Pharmacol Drug Dev· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1 Renal Impairment Trial Results Supports Targeted Individualized Dosing of ELX-02 in Patients With Nephropathic Cystinosis.
Thomas Haverty, David J Wyatt, Kaela M Porter, Andi Leubitz, Kate Banks

J Clin Pharmacol· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses of ELX-02, a Potential Treatment for Genetic Disorders Caused by Nonsense Mutations, in Healthy Volunteers.
Andi Leubitz, Anat Frydman-Marom, Neal Sharpe, John van Duzer, Kathleen C M Campbell

Clin Pharmacol Drug Dev· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis